AXIM Share Price Performance
US$0.0072
0.00 (140.00%)
Price US$0.0072
Share PriceUS$0.0072
AXIM Biotechnologies, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
AXIM Community Narratives
There are no narratives available yet.
Recent AXIM News & Updates
AXIM Biotechnologies, Inc. Key Details
Last Reported Earnings
Jun 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.012
- Gross Margin
- 98.12%
- Net Profit Margin
- -4,452.06%
- Debt/Equity Ratio
- -69.2%
AXIM Biotechnologies, Inc. Competitors
Snowflake Analysis
About AXIM
- Founded
- 2010
- Employees
- 7
- CEO
- WebsiteView website
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: 0.8%
- 3 Months: 8.3%
- 1 Year: 17.8%
- Year to Date: 15.4%
The Utilities sector gained 3.1% while the market remained flat over the last week. As for the longer term, the market has risen 18% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›